Gilead Sciences, Inc.
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 13, 2025), Gilead Sciences, Inc. reported 14 stock positions worth $1.2 billion. Its top holding was Arcellx (ACLX) at 37.3% of the portfolio, followed by Lakefront Biotherapeutic-ADR (LKFT, 35.5%) and Arcus Biosciences (RCUS, 20.9%). Compared with Q4 2024, it opened 1 new position, sold out of 3, added to 1 and reduced 2. The biggest buy was a new position in Kalaris Therapeutics (KLRS) and the biggest sale an exit from Allovir.
- Most Recent 13F
- Q2 2026
- Location
- FOSTER CITY, CA
- CIK
- 0000882095
- Portfolio Value
- $1.2B (Q1 2025)
- SEC Filing
- 0001123292-25-000217 ↗ filed May 13, 2025
Holdings Value
Holdings 14 stocks · $1.2B
| ACLX Arcellx Inc. | 37.32% | 6,720,803 | $440.9M | No change |
| LKFT Lakefront Biotherapeutic-ADR filed as GALAPAGOS NV | 35.50% | 16,707,477 | $419.4M | No change |
| RCUS Arcus Biosciences Inc. | 20.88% | 31,424,760 | $246.7M | Add +4.5% |
| ASMB Assembly Biosciences Inc. | 1.79% | 2,209,471 | $21.1M | No change |
| MRUS Merus NV | 1.61% | 452,527 | $19.0M | No change |
| KYTX Kyverna Therapeutics Inc. | 0.67% | 4,126,119 | $8.0M | No change |
| TNGX Tango Therapeutics Inc. | 0.56% | 4,854,443 | $6.7M | No change |
| XLO Xilio Therapeutics Inc. | 0.56% | 9,105,451 | $6.6M | No change |
| KLRS Kalaris Therapeutics Inc. | 0.49% | 723,273 | $5.8M | New |
| HOOK Hookipa Pharma Inc. | 0.17% | 1,875,945 | $2.0M | No change |
| ALLO Allogene Therapeutics Inc. | 0.14% | 1,156,689 | $1.7M | No change |
| CYPH Cypherpunk Technologies Inc. filed as LEAP THERAPEUTICS INC | 0.14% | 5,319,148 | $1.6M | No change |
| IKENA ONCOLOGY INC | 0.13% | 1,159,145 | $1.5M | Reduce -42.3% |
| BRNS Barinthus Biotherapeutics PL | 0.03% | 369,855 | $360K | Reduce -40.4% |
Portfolio Sells Q4 2024 → Q1 2025
| ALLOVIR INC | Sold out | 0.00% | −0.45 |
| IKENA ONCOLOGY INC | Reduce -42.3% | 0.13% | −0.09 |
| AGEN Agenus Inc. | Sold out | 0.00% | −0.04 |
| BRNS Barinthus Biotherapeutics PL | Reduce -40.4% | 0.03% | −0.02 |
| KRON Kronos Bio Inc. | Sold out | 0.00% | −0.01 |
Portfolio Buys Q4 2024 → Q1 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 5 | $1.6B | RCUS, LKFT, ASMB, KYTX, XLO |
| Q1 2026 | 6 | $2.1B | ACLX, RCUS, LKFT, ASMB, KYTX |
| Q4 2025 | 6 | $1.9B | RCUS, LKFT, ACLX, ASMB, KYTX |
| Q3 2025 | 9 | $1.8B | LKFT, ACLX, RCUS, ASMB, MRUS |
| Q2 2025 | 14 | $1.3B | LKFT, ACLX, RCUS, ASMB, TNGX |
| Q1 2025 | 14 | $1.2B | ACLX, LKFT, RCUS, ASMB, MRUS |
| Q4 2024 | 16 | $1.6B | ACLX, LKFT, RCUS, ASMB, MRUS |